Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Madrigal Pharmaceuticals
Pharma
Madrigal builds launch infrastructure for MASH drug Rezdiffra
Despite a reimbursement hurdle from the VA, Madrigal is still targeting 80% commercial coverage for its MASH drug Rezdiffra by year-end.
Angus Liu
May 7, 2024 11:56am
89bio lines up BiBo Pharma to build $135M commercial API plant
Apr 11, 2024 3:23pm
Docs sing praises of Madrigal's Rezdiffra, predict rapid uptake
Apr 8, 2024 7:45am
After MASH OK, Madrigal plots $600M stock sale to support launch
Mar 19, 2024 5:17pm
FDA approves first drug for MASH in Madrigal's Rezdiffra
Mar 14, 2024 3:56pm
‘The Top Line’: The most anticipated drug launches of 2024
Feb 9, 2024 6:00am